European regulators to review GSK's asthma drug Nucala to treat COPD
The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
Zacks Investment Research on MSN4d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...
GSK says European regulator reviewing expanded use of asthma drug Nucala
GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...
Yahoo Finance3d
EMA to review GSK’s Nucala for COPD treatment expansion
The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary ...
GSK application to expand use of Nucala to COPD accepted for review by EMA
GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...
Healio1d
Mepolizumab lowers repeat surgery risk for CRSwNP regardless of number of past surgeries
Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...
Devdiscourse4d
Health Turmoil: Rising TB, Strategic Drug Reviews, and Food Safety Shifts
A 10% surge in child TB infections in Europe has prompted urgent WHO action, European regulators are evaluating GSK's drug ...
Devdiscourse3d
Global Health Concerns: Rising TB, Bird Flu in Mammals, and Pharmaceutical Updates
Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic ...
Pharmabiz2d
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...
Nasdaq4d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab).